COST OF LONG-ACTING RISPERIDONE INJECTION VERSUS LONG-ACTING PALIPERIDONE PALMITATE IN PATIENTS WITH SCHIZOPHRENIA IN RUSSIA

被引：0
|
作者：
Omelyanovsky, V [1 ]
Avxentyeva, M. [1 ]
Ivakhnenko, O. [1 ]
Khailov, P. [1 ]
Tsfasman, F. M. [1 ]
Krysanov, I [1 ]
Zorin, N. [1 ]
机构：
[1] Russian Natl Res Med Univ, Res Ctr Clin & Econ Evaluat & Pharmacoecon, Moscow, Russia
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A338 / A338
页数：1
相关论文
共 50 条
  • [1] Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain
    Javier Quintero
    Itziar Oyagüez
    Beatriz González
    Ignacio Cuervo-Arango
    Ignacio García
    Miguel Angel Casado
    Clinical Drug Investigation, 2016, 36 : 479 - 490
  • [2] Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain
    Quintero, Javier
    Oyaguez, Itziar
    Gonzalez, Beatriz
    Cuervo-Arango, Ignacio
    Garcia, Ignacio
    Angel Casado, Miguel
    CLINICAL DRUG INVESTIGATION, 2016, 36 (06) : 479 - 490
  • [3] A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia
    Fleischhacker, W. Wolfgang
    Gopal, Srihari
    Lane, Rosanne
    Gassmann-Mayer, Cristiana
    Lim, Pilar
    Hough, David
    Remmerie, Bart
    Eerdekens, Marielle
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 (01): : 107 - 118
  • [4] Paliperidone palmitate long-acting injection in schizophrenic patients
    Suarez Gisbert, E.
    EUROPEAN PSYCHIATRY, 2020, 63 : S540 - S540
  • [5] Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison
    Fu, Dong-Jing
    Bossie, Cynthia A.
    Sliwa, Jennifer K.
    Ma, Yi-Wen
    Alphs, Larry
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (01) : 45 - 55
  • [6] COST-EFFECTIVENESS OF LONG-ACTING OLANZAPINE VERSUS LONG-ACTING RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA IN SPAIN
    Dilla, T.
    O'Donohoe, P.
    Moeller, J.
    Alvarez, M.
    Sacristan, J.
    San, L.
    Happich, M.
    Tockhorn, A.
    VALUE IN HEALTH, 2011, 14 (07) : A292 - A292
  • [7] Cost-effectiveness analysis of paliperidone palmitate versus long-acting risperidone as maintenance treatment in schizophrenia patients in Italy
    Ravasio, Roberto
    Nicole, Giuseppe
    Vaggi, Marco
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2015, 2 (01) : 17 - 32
  • [8] COST EFFECTIVENESS OF PALIPERIDONE PALMITATE VERSUS RISPERIDONE LONG-ACTING INJECTABLE, QUETIAPINE AND OLANZAPINE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA IN COLOMBIA
    Casallas, C.
    Ariza, J. G.
    VALUE IN HEALTH, 2013, 16 (07) : A695 - A695
  • [9] A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia
    Li, Huafang
    Rui, Qing
    Ning, Xiaoping
    Xu, Haiyan
    Gu, Niufan
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (04): : 1002 - 1008
  • [10] Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison
    Dilla, Tatiana
    Moeller, Joergen
    O'Donohoe, Paul
    Alvarez, Maria
    Sacristan, Jose A.
    Happich, Michael
    Tockhorn, Antje
    BMC PSYCHIATRY, 2014, 14
12345